Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 276

1.

The PD1/PDL1 axis, a promising therapeutic target in aggressive breast cancers.

Bertucci F, Finetti P, Birnbaum D, Mamessier E.

Oncoimmunology. 2015 Aug 31;5(3):e1085148. eCollection 2016 Mar.

PMID:
27141340
2.

Expression of Genes with Copy Number Alterations and Survival of Patients with Pancreatic Adenocarcinoma.

Birnbaum DJ, Bertucci F, Finetti P, Adélaïde J, Giovannini M, Turrini O, Delpero JR, Raoul JL, Chaffanet M, Moutardier V, Birnbaum D, Mamessier E.

Cancer Genomics Proteomics. 2016 05-06;13(3):191-200.

PMID:
27107061
3.

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

Mir O, Cropet C, Toulmonde M, Cesne AL, Molimard M, Bompas E, Cassier P, Ray-Coquard I, Rios M, Adenis A, Italiano A, Bouché O, Chauzit E, Duffaud F, Bertucci F, Isambert N, Gautier J, Blay JY, Pérol D; PAZOGIST study group of the French Sarcoma Groupe-Groupe d'Etude des Tumeurs Osseuses (GSF-GETO).

Lancet Oncol. 2016 Apr 5. pii: S1470-2045(16)00075-9. doi: 10.1016/S1470-2045(16)00075-9. [Epub ahead of print]

PMID:
27068858
4.

Highly favorable outcome in BRCA-mutated metastatic breast cancer patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation.

Boudin L, Gonçalves A, Sabatier R, Moretta J, Sfumato P, Asseeva P, Livon D, Bertucci F, Extra JM, Tarpin C, Houvenaegel G, Lambaudie E, Tallet A, Resbeut M, Sobol H, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Viens P, Eisinger F, Chabannon C.

Bone Marrow Transplant. 2016 Apr 4. doi: 10.1038/bmt.2016.82. [Epub ahead of print]

PMID:
27042835
5.

Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.

Bertucci F, Fekih M, Autret A, Petit T, Dalenc F, Levy C, Romieu G, Bonneterre J, Ferrero JM, Kerbrat P, Soulie P, Mouret-Reynier MA, Bachelot T, Lerebours F, Eymard JC, Deblock M, Lortholary A, Hardy-Bessard AC, Barthelemy P, Bonnefoi H, Charafe-Jauffret E, Bidard FC, Viens P, Lemonnier J, Pierga JY.

Lancet Oncol. 2016 Mar 28. pii: S1470-2045(16)00011-5. doi: 10.1016/S1470-2045(16)00011-5. [Epub ahead of print]

PMID:
27032301
6.

Comparative genomic analysis of primary tumors and metastases in breast cancer.

Bertucci F, Finetti P, Guille A, Adélaïde J, Garnier S, Carbuccia N, Monneur A, Charafe-Jauffret E, Goncalves A, Viens P, Birnbaum D, Chaffanet M.

Oncotarget. 2016 Mar 25. doi: 10.18632/oncotarget.8349. [Epub ahead of print]

7.

Management of desmoid tumours: A nationwide survey of labelled reference centre networks in France.

Penel N, Coindre JM, Bonvalot S, Italiano A, Neuville A, Le Cesne A, Terrier P, Ray-Coquard I, Ranchere-Vince D, Robin YM, Isambert N, Ferron G, Duffaud F, Bertucci F, Rios M, Stoeckle E, Le Pechoux C, Guillemet C, Courreges JB, Blay JY.

Eur J Cancer. 2016 May;58:90-6. doi: 10.1016/j.ejca.2016.02.008. Epub 2016 Mar 11.

8.

PLZF mutation alters mouse hematopoietic stem cell function and cell cycle progression.

Vincent-Fabert C, Platet N, Vandevelde A, Poplineau M, Koubi M, Finetti P, Tiberi G, Imbert AM, Bertucci F, Duprez E.

Blood. 2016 Apr 14;127(15):1881-5. doi: 10.1182/blood-2015-09-666974. Epub 2016 Mar 3.

PMID:
26941402
9.

Genomic Characterization of Primary Invasive Lobular Breast Cancer.

Desmedt C, Zoppoli G, Gundem G, Pruneri G, Larsimont D, Fornili M, Fumagalli D, Brown D, Rothé F, Vincent D, Kheddoumi N, Rouas G, Majjaj S, Brohée S, Van Loo P, Maisonneuve P, Salgado R, Van Brussel T, Lambrechts D, Bose R, Metzger O, Galant C, Bertucci F, Piccart-Gebhart M, Viale G, Biganzoli E, Campbell PJ, Sotiriou C.

J Clin Oncol. 2016 Feb 29. pii: JCO640334. [Epub ahead of print]

PMID:
26926684
10.

MMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.

Tabouret E, Bertucci F, Pierga JY, Petit T, Levy C, Ferrero JM, Campone M, Gligorov J, Lerebours F, Roché H, Bachelot T, van Laere S, Ueno NT, Toiron Y, Finetti P, Birnbaum D, Borg JP, Viens P, Chinot O, Gonçalves A.

Oncotarget. 2016 Feb 23. doi: 10.18632/oncotarget.7612. [Epub ahead of print]

11.

Immunohistochemical subtypes predict survival in metastatic breast cancer receiving high-dose chemotherapy with autologous haematopoietic stem cell transplantation.

Boudin L, Chabannon C, Sfumato P, Sabatier R, Bertucci F, Tarpin C, Provansal M, Houvenaegel G, Lambaudie E, Tallet A, Resbeut M, Charafe-Jauffret E, Calmels B, Lemarie C, Boher JM, Extra JM, Viens P, Gonçalves A.

Eur J Cancer. 2016 Apr;57:118-26. doi: 10.1016/j.ejca.2016.01.005. Epub 2016 Feb 23.

PMID:
26918737
12.

Management and prognosis of malignant peripheral nerve sheath tumors: The experience of the French Sarcoma Group (GSF-GETO).

Valentin T, Le Cesne A, Ray-Coquard I, Italiano A, Decanter G, Bompas E, Isambert N, Thariat J, Linassier C, Bertucci F, Bay JO, Bellesoeur A, Penel N, Le Guellec S, Filleron T, Chevreau C.

Eur J Cancer. 2016 Mar;56:77-84. doi: 10.1016/j.ejca.2015.12.015. Epub 2016 Jan 26.

PMID:
26824706
13.

Identification of p62/SQSTM1 as a component of non-canonical Wnt VANGL2-JNK signalling in breast cancer.

Puvirajesinghe TM, Bertucci F, Jain A, Scerbo P, Belotti E, Audebert S, Sebbagh M, Lopez M, Brech A, Finetti P, Charafe-Jauffret E, Chaffanet M, Castellano R, Restouin A, Marchetto S, Collette Y, Gonçalvès A, Macara I, Birnbaum D, Kodjabachian L, Johansen T, Borg JP.

Nat Commun. 2016 Jan 12;7:10318. doi: 10.1038/ncomms10318.

14.

METRO1: A Phase I Study of Metronomic Chemotherapy in Adults with Advanced Refractory Solid Tumors.

Launay S, Sabatier R, Brunelle S, Esterni B, Tarpin C, Viret F, Gravis G, Cappiello M, Provansal M, Extra JM, Bertucci F, Viens P, Goncalves A.

Anticancer Res. 2016 Jan;36(1):293-9.

PMID:
26722056
15.

Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.

Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre JM, Bui-Nguyen B, Adenis A, Rios M, Bertucci F, Duffaud F, Chevreau C, Cupissol D, Pérol D, Emile JF, Blay JY, Le Cesne A; French Sarcoma Group.

Eur J Cancer. 2016 Jan;52:173-80. doi: 10.1016/j.ejca.2015.10.069. Epub 2015 Dec 11.

PMID:
26687836
16.

HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers.

Putcha P, Yu J, Rodriguez-Barrueco R, Saucedo-Cuevas L, Villagrasa P, Murga-Penas E, Quayle SN, Yang M, Castro V, Llobet-Navas D, Birnbaum D, Finetti P, Woodward WA, Bertucci F, Alpaugh ML, Califano A, Silva J.

Breast Cancer Res. 2015 Dec 8;17(1):149. doi: 10.1186/s13058-015-0658-0.

17.

High-grade soft tissue sarcoma arising in a desmoid tumor: case report and review of the literature.

Bertucci F, Faure M, Ghigna MR, Chetaille B, Guiramand J, Moureau-Zabotto L, Sarran A, Perrot D.

Clin Sarcoma Res. 2015 Nov 30;5:25. doi: 10.1186/s13569-015-0040-0. eCollection 2015.

18.

Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a.

Wolfe AR, Debeb BG, Lacerda L, Larson R, Bambhroliya A, Huang X, Bertucci F, Finetti P, Birnbaum D, Van Laere S, Diagaradjan P, Ruffell B, Trenton NJ, Chu K, Hittelman W, Diehl M, Levental I, Ueno NT, Woodward WA.

Breast Cancer Res Treat. 2015 Dec;154(3):495-508. doi: 10.1007/s10549-015-3645-3. Epub 2015 Nov 21.

PMID:
26590814
19.

Immunohistochemical subtypes predict the clinical outcome in high-risk node-negative breast cancer patients treated with adjuvant FEC regimen: results of a single-center retrospective study.

Rahal S, Boher JM, Extra JM, Tarpin C, Charafe-Jauffret E, Lambaudie E, Sabatier R, Thomassin-Piana J, Tallet A, Resbeut M, Houvenaeghel G, Laborde L, Bertucci F, Viens P, Gonçalves A.

BMC Cancer. 2015 Oct 14;15:697. doi: 10.1186/s12885-015-1746-3.

20.

H19 non coding RNA-derived miR-675 enhances tumorigenesis and metastasis of breast cancer cells by downregulating c-Cbl and Cbl-b.

Vennin C, Spruyt N, Dahmani F, Julien S, Bertucci F, Finetti P, Chassat T, Bourette RP, Le Bourhis X, Adriaenssens E.

Oncotarget. 2015 Oct 6;6(30):29209-23. doi: 10.18632/oncotarget.4976.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk